enign familial chronic pemphigus (HHD) is a rare autosomal dominant genodermatosis characterized by development of recurrent blisters, erosions and crustrations in the intertriginous areas; especially the axilla and groin. Mutations in the ATP2C1 gene which encodes a Ca +2 ATPase, hSPCA1, that is located on the Golgi membrane of keratinocytes are thought to be the underlying pathology.
Successful Treatment of Hailey-Hailey Disease with Systemic Cyclosporine: Case Report A AB BS ST TR RA AC CT T Hailey-Hailey disease (HHD) is a rare disease that affects the adhesion of epidermal keratinocytes. It is characterized by erosions and crustrations primarily in intertriginous areas. Treatment options include topical antibiotics, antifungals, corticosteroids, dapsone, photo chemotherapy, systemic retinoids, cyclosporine, methotrexate and photodynamic therapy. Here we report a 56 years old female with refractory HHD that is succesfully treated with cyclosporine. The patient had been treated with topical steroids, antifungals, antimicrobials and topical calcineurin inhibitors with limited success. Systemic treatment with methotrexate (15 mg weekly) and acitretin (25 mg daily) were also unsuccessful. Cyclosporine was started 2.5 mg/kg/day and resulted in almost complete clearance of lesions after a month. The dose of cyclosporine was reduced gradually and stopped at the end of sixth months. Topical antibiotics and topical tacrolimus were used for minor recurrences. Short course of cyclosporine can be an alternative for refractory HHD. Treatment alternatives include topical antibiotics, antifungals, corticosteroids and calcineurin inhibitors. In resistant cases systemic agents such as dapsone, psoralen ultraviolet A (PUVA), retinoids, cyclosporine, methotrexate and photodynamic therapy may be helpful.
CASE REPORT
A 56-year-old female patient referred to our clinic with painful erythematous erosions in groins, axilla and infra-mammary area ( Figure 1 ). Similar complaints have persisted for 20 years with varying severity. In the biopsy taken from the patient, acantholysis and a bulla characterized by suprabasal cleavage were seen in the epidermis. The loss of spinous processes in keratinocytes extending into the bulla has been noted. Mixed type inflammatory cell infiltration with mononuclear lymphocytes dominance accompanied by eosinophil leukocytes was observed in the peribullous areas of the dermis and perivascular areas (Figure 2) . Before applying to us, the patient used topical corticosteroids, antifungals and systemic antimicrobial agents such as terbinafine, doxycycline and itraconazole, but had no benefit. The patient remembered that there were similar lesions in her mother too. The patient was accepted as HaileyHailey disease with his current dermatological examination, biopsy and family history.
Earlier in the disease course the patient was given topical corticosteroids, topical and systemic antimicrobial agents in addition to general precautions such as wearing appropriate clothes to minimize friction and sweating. She was followed for six months on this regimen with no improvement. One session of fractionated CO 2 laser application resulted in the aggrevation of lesions. Subcutaneous methotrexate 15 mg per week was added to topical therapy for 3 months without improvement and the treatment was changed to oral acitretin 25 mg per day. After treatment with acitretin for one month, her symptoms aggravated with excessive xerosis of lips, hands and feet. Acitretin was stopped and cyclosporine 2.5 mg/kg/day was started. Almost all symptoms improved within a month ( Figure 3) . Cyclosporine was tapered down to 1.5 mg/kg/day for maintenance for 5 months and patient remained in remission. The patient was followed up for 1 year after the cessation of systemic cyclosporine and did well on occasional topical antibiotics and topical tacrolimus for minor exacerbations ( Figure 4 shows the patient's axillar and inguinal region six months after the cessation of systemic cyclosporine). Because of a major recurrence, 2,5 mg/kg/day cyclosporine was started again after a year, and lesions regressed. As a result, the use of cyclosporine in these exacerbations was seen as the best option in this case. Gökhan Topical and systemic antimicrobial agents may be required because secondary bacterial, fungal and viral infections play a substantial role in disease aggravation and persistence. Histopathology of HHD reveals prominent acantholysis in the suprabasillary epidermis that extends towards the upper layers which is also known as "the dilapidated brick wall appearance". Treatment starts with general precautions such as wearing appropriate clothes to minimize friction and sweating. To prevent colonization and secondary bacterial, fungal and viral infections, topical and systemic antimicrobial agents should be used along with suitable cleansers. When used in early stages of the lesions, topical corticosteroids are effective in many cases.
3 Topical corticosteroid resistant patients may respond to intralesional injections. Case reports suggest that topical tacrolimus, 5-fluorouracil, calcitriol, tacalcitiol and botulinum toxin may also be of use in terms of local therapy. 1 Superficial ablative techniques including dermabrasion, CO 2 -Erbium:YAG laser, photodynamic therapy with 5-ALA are equally effective and have replaced aggressive surgical approaches. 4, 5 Some studies suggest systemic therapy with retinoids, prednisone, cyclosporine, methotrexate and dapsone can be helpful. 1 The effectiveness of cyclosporine monotherapy 6, 8 or combination 2 with other immunomodulatory agents in HHD has been shown in only a few cases. Dose of cyclosporine in these cases ranged between 2.5-5 mg/kg/day and time period to induce remission and relapse after discontinuation were diverse. Berth-Jones and colleagues reported a patient with severe exudation and pain attacks in the axilla and groin, despite using long-term topical 0.05% cobetasol propionate, who showed marked improvement after 16 weeks of cyclosporine at 2.8 to 3.4 mg/kg/day, but relapsed after discontinuation. 6 Ormerod and colleagues used slightly higher doses (5 mg/kg/day) for two patients that had previously been partial and temporary improvement in oral topical steroids, dapsone, methotrexate and PUVA treatments in whom rapid response was obtained and sustained even after the dose was lowered. 7 Nanda et al. reported a patient with partial healing with oral and topical antibiotics, topical antifungal, corticosteroids and dapsone treatments whose lesions completely cleared 3 weeks after starting cyclosporine at 2.5 mg/kg/day and did not relapse significantly even after discontinuation. 8 Varada et al. added cyclosporine 2.8 mg/kg/day, then increased the dose to 3.8 mg/kg/day in a patient did not receive satisfactory treatment with acitretin 50 mg/day that previously used topical corticosteroids, prednisone, isotretinoin, etanercept and various antibiotics. Acitretin was reduced to 25 mg/day after that, and significant improvement was observed in the lesions of the patient at the end of the sixth month. 2 Since cyclosporine has well known systemic toxicity, starting with lower doses and adjusting the dose according to the clinical response is necessary.
The mechanism of action of cyclosporine in HHD pathophysiology is not well understood. It is likely that suppression of certain proinflammatory cytokine secretion and restoration of ATP2C1 mRNA levels that are increased by UVB exposure play a role. 9 Another theory suggests that cyclosporine plays a role in intracellular calcium regulation that may improve cell to cell adhesion in the epidermis. 10 Whatever the mechanism, it appears effective but relapse after discontinuation is usual.
In conclusion, we suggest that low dose cyclosporine can be considered as a rescue therapy for the treatment of refractory HHD to induce remission with a relatively short course of maintenance therapy in order to avoid toxicity related to long term use of this drug. After induction of remission, rotation to other immunmodulatory agents such as acitretin or combination with dose A Au ut th ho or rs sh hi ip p C Co on nt tr ri ib bu ut ti io on ns s W Wr ri it ti in ng g M Ma an nu us sc cr ri ip pt t, , D Di is sc cu us ss si io on n a an nd d S Su up pp pl ly yi in ng g R Re es so ou ur rc ce es s: :
Gökhan Şahin and Seda Koç Şahin; C Co on nc ce ep pt t, , D De es si ig gn n, , A An na al ly ys si is s a an nd d W Wr ri it ti in ng g M Ma an nu us sc cr ri ip pt t: : Gökhan Şahin ve Nilgün Şentürk; C Cr ri it ti ic ca al l R Re ev vi ie ew w: : Nilgün Şentürk.
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